Even after its passage in 2024, the investor and mathematician billionaire Jim Simons is still known as the “King How much” in coverage funds due to the extraordinary success of Renaissance technologiesYour quantitative negotiation company based in New York. After years of financial industry research, Simons realized the potential without exploiting quantitative analyzes to take advantage of market inefficiencies. This vision led him to develop an investment strategy based on data to analyze market behavior only through statistical and mathematical models. By identifying the subtle patterns and not random in financial data, the genius as much predicted future movements of the actions and generated impressive returns.
Although closed to external investors, the secret fund of the medallion of Jim Simons, a Renaissance flagship, has produced innovative results since its inception. The Medallion Fund gained impressive returns of 56.6% and 74.6% during the first Dot-Compe accident in the early 2000’s and the world financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $ 31.4 billion, placing it among the richest individuals in the world, thanks to the strong performance of the Market Market Medallion and Renaissance.
The Renaissance Technologies computer based power plant began to begin after stellar realization in 2024. The Renaissance diversified Alpha Fund 11.85% in the first two months of 2025. Both funds can maintain important positions of individual stock, as well as use future actions index and options to help manage the risk. However, the firm warns that it may be difficult to quickly undo these important stakes without affecting market prices.
For this list, we have chosen actions of the Renaissance Technologies 13f portfolio in the late quarter of 2024. These actions are also popular with elite coverage funds.
Why are we interested in the stocks that cover the funds? The reason is simple: our research has shown that we can overcome the market by imitating the best stock options for the best coverage funds. The strategy of our quarterly bulletin selects 14 stocks of small layers and large layers each quarter and has returned 373.4% since May 2014, surpassing its reference point at 218 percentage points (Check out more details here)).
Exelixis, Inc. (Exel) Is the best stock to buy according to Jim Simons Renaissance technologies?
A team of laboratory coats scientists surrounded by pharmaceuticals and medical equipment, researching a biotechnology focused on oncology of life.
Renaissance Technologies Q4 bet: $ 509.3 million
Number of coverage fund holders: 46
Exelixis, Inc. (NASDAQ: Exel) It focuses on developing directed cancer treatments. The company specializes in molecular therapies that deal with cancers that are difficult to treat by addressing particular mutations to the genome.
Exelixis, Inc. (Nasdaq: Exel) He has received the approval of the FDA for his drug Cabozantinib, also known as Cabometyx, to treat certain neuroendocrine (net) tumors, marking the company’s sixth approval in the United States. This decision was based on the stage 3 cabinet process, which demonstrated significant improvements in average survival without progression for pancreatic and extra-pancreatic networks.
On April 17, CITIZENS Analysts JMP maintained a higher market rating in Exelixis, Inc. (NASDAQ: Exel), with a price of $ 41 price. Silvan Tuerkcan, an analyst of the firm, predicted that exempting would exceed the upper line, attributing to a strong prescription model. Due to the restrictions on the growth of the WAC imposed by the Act of Reduction of Inflation, Exerixis, Inc. (NASDAQ: Exel) experienced a slight year -on -year growth of 2.8%. Exelix reports Cabozantinib sales of $ 473.5 million, representing a decrease of 8% over the previous quarter, but a 26% year -on -year increase. The same percentage of growth and decrease for clean sales of products are expected.
Overall exel occupies 9th place In our list of best shares to buy according to Renaissance technologies by Jim Simons. Although we recognize exel potential as an investment, our conviction lies in the belief that some AI actions have a greater promise to obtain higher yields and do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of Ia most promising than exel but sells less than five times, see our report on this Ia stock cheap.
